|Bid||5.35 x 1100|
|Ask||5.71 x 800|
|Day's range||5.37 - 5.79|
|52-week range||4.81 - 12.61|
|Beta (5Y monthly)||0.85|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Alzheimer's drug developer AC Immune expects the number of families to be affected by the degenerative disease could nearly triple by 2050 to 150 million, its CEO said in an interview with a German magazine. The company recently secured a multi-million investment from the main backers of German COVID-19 vaccine developer BioNTech while acquiring a possible Parkinson's disease vaccine. AC Immune's CEO Andrea Pfeifer, in an interview with German business magazine Wirtschaftswoche published in its online edition on Sunday, described Alzheimer's, a non-curable disease the origin of which is not known, as "a slow pandemic rolling towards the world".
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.